Beset by fierce competition and price erosion in its core generics business, particularly in the US, Novartis’ Sandoz division is undertaking an ambitious transformational shift that the group believes will deliver sustainable growth at considerably improved profit margins.
A concerted effort to streamline its manufacturing base and optimize supply-chain efficiency is already underway, contributing in 2018 to a...






